Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

3.926 -0.314 (-7.41%)
Streaming Delayed Price Updated: 3:54 PM EDT, Jul 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 Next >
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Resignation of Board Member
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at Upcoming Investor Conferences in March
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Reports Full Year 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Reports Q3 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
From AbCellera Biologics Inc.
Via Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader 
From Prelude Therapeutics, Inc.; AbCellera
Via GlobeNewswire
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
From AbCellera Biologics Inc.
Via Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Reports Q2 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Reports Q1 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023
From AbCellera Biologics Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.